慢性丙型肝炎抗病毒治疗专家共识

被引：70

作者：

谢尧

范小玲

杨松

机构：

[1] 慢性丙型肝炎抗病毒治疗专家委员会

来源：

中华实验和临床感染病杂志(电子版) | 2009年 / 3卷 / 03期

关键词：

D O I：

暂无

中图分类号：

R512.63 [];

学科分类号：

摘要：

引用

页码：343 / 352

页数：10

共 18 条

[1]

丙型肝炎防治指南.[J]..中华肝脏病杂志.2004, 04

[2]

Diagnosis, Management, and Treatment of Hepatitis C: An Update [J].

Ghany, Marc G. ;

Strader, Doris B. ;

Thomas, David L. ;

Seeff, Leonard B. .

HEPATOLOGY, 2009, 49 (04) :1335-1374

[3]

Hepatitis B virus/hepatitis C virus coinfection: Epidemiology, clinical features, viral interactions and treatment [J].

Chu, Chi-Jen ;

Lee, Shou-Dong .

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2008, 23 (04) :512-520

[4]

Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons [J].

Alvarez, D. ;

Dieterich, D. T. ;

Brau, N. ;

Moorehead, L. ;

Ball, L. ;

Sulkowski, M. S. .

JOURNAL OF VIRAL HEPATITIS, 2006, 13 (10) :683-689

[5]

Helbling, Beat ;

Jochum, Wolfram ;

Stamenic, Ivan ;

Knoepfli, Marina ;

Cerny, Andreas ;

Borovicka, J. ;

Gonvers, Jean-Jacques ;

Wilhelmi, Martin ;

Dinges, Sabine ;

Muellhaupt, Beat ;

Esteban, Alicia ;

Meyer-Wyss, Beat ;

Renner, Eberhard L. .

JOURNAL OF VIRAL HEPATITIS, 2006, 13 (11) :762-769

[6]

Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment [J].

Sanchez-Tapias, Jose M. ;

Diago, Moises ;

Escartin, Pedro ;

Enriquez, Jaime ;

Romero-Gomez, Manuel ;

Barcena, Rafael ;

Crespo, Javier ;

Andrade, Raul ;

Martinez-Bauer, Eva ;

Perez, Ramon ;

Testillano, Milagros ;

Planas, Ramon ;

Sola, Ricard ;

Garcia-Bengoechea, Manuel ;

Garcia-Samaniego, Javier ;

Munoz-Sanchez, Miguel ;

Moreno-Otero, Ricardo .

GASTROENTEROLOGY, 2006, 131 (02) :451-460

[7]

Pegylated interferon alfa-2b plus ribavirin in the retreatment of interferon-ribavirin nonresponder patients [J].

Taliani, G ;

Gemignani, G ;

Ferrari, C ;

Aceti, A ;

Bartolozzi, D ;

Blanc, PL ;

Capanni, M ;

Esperti, F ;

Forte, P ;

Guadagnino, V ;

Mari, T ;

Marino, N ;

Milani, S ;

Pasquazzi, C ;

Rosina, F ;

Tacconi, D ;

Toti, M ;

Zignego, AL ;

Messerini, L ;

Stroffolini, T .

GASTROENTEROLOGY, 2006, 130 (04) :1098-1106

[8]

Extended treatment duration for hepatitis C virus type 1: Comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin [J].

Berg, T ;

von Wagner, M ;

Nasser, S ;

Sarrazin, C ;

Heintges, T ;

Gerlach, T ;

Buggisch, P ;

Goeser, T ;

Rasenack, J ;

Pape, GR ;

Schmidt, WE ;

Kallinowski, B ;

Klinker, H ;

Spengler, U ;

Martus, P ;

Alshuth, U ;

Zeuzem, S .

GASTROENTEROLOGY, 2006, 130 (04) :1086-1097

[9]

Pegylated interferon and ribavirin failures: Is retreatment an option? [J].

Cheruvattath, Rekha ;

Rosati, Marianne J. ;

Gautam, Manjushree ;

Vargas, Hugo E. ;

Rakela, Jorge ;

Balan, Vijayan .

DIGESTIVE DISEASES AND SCIENCES, 2007, 52 (03) :732-736

[10]

Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40<ce:hsp sp="0.25"/>KD)/ribavirin.[J]..Journal of Hepatology.2005, 3

← 1 2 →